The RELIEVE UCCD long-term extension study has shown that duvakitug, a human monoclonal antibody targeting TL1A developed by Sanofi and Teva Pharmaceutical Industries, maintained robust efficacy over 44 weeks in patients with ulcerative colitis and Crohn’s disease who initially responded during induction therapy.
In ulcerative colitis, clinical remission was achieved by 58% of patients on the 900 mg dose and 47% on the 450 mg dose at week 44. For Crohn’s disease, endoscopic response rates reached 55% and 41% for the respective doses. The safety profile remained consistent with the induction study, with upper respiratory tract infection and nasopharyngitis as the most commonly observed adverse events.
Duvakitug works by preferentially inhibiting TL1A-DR3 signaling to reduce inflammation and fibrosis in inflammatory bowel disease. The drug is currently in Phase 3 development for both ulcerative colitis and Crohn’s disease, building on these maintenance results that suggest durable treatment benefit.